ORKA

Oruka Therapeutics Inc

Add to Watchlist

Advanced Chart

13.730

-0.28(-1.999%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

14.370

Open

14.160

VWAP

Vol

100.66K

Mkt Cap

514.06M

Low

13.580

Amount

EV/EBITDA(TTM)

Total Shares

37.44M

167.90M

EV/OCF(TTM)

P/S(TTM)

Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).

7 Analyst Rating

216.82% Upside

Wall Street analysts forecast ORKA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ORKA is 43.50 USD with a low forecast of 40.00 USD and a high forecast of 47.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

0 Hold

0 Sell

Strong Buy

216.82% Upside

Current: 13.730

Low

40.00

Averages

43.50

High

47.00

216.82% Upside

Current: 13.730

Low

40.00

Averages

43.50

High

47.00

BTIG

NULL

Buy

initiated

$44

2025-05-22

Reason

BTIG

Price Target

$44

2025-05-22

initiated

NULL

Buy

Reason

BTIG initiated coverage of Oruka Therapeutics with a Buy rating and $44 price target. The firm, which expects Oruka's ORKA-001 and ORKA-002 monoclonal antibodies to thrive as monotherapies and also potentially in combination, sees "compelling reasons to believe" that ORKA-001 and ORKA-021 could eventually be confirmed with differentiated efficacy in the indications of psoriasis and psoriatic arthritis.

HC Wainwright & Co.

Mitchell Kapoor

Strong Buy

Reiterates

$45

2025-02-07

Reason

HC Wainwright & Co.

Mitchell Kapoor

Price Target

$45

2025-02-07

Reiterates

Strong Buy

Reason

Wolfe Research

Andy Chen

Buy

Initiates

$20

2025-02-04

Reason

Wolfe Research

Andy Chen

Price Target

$20

2025-02-04

Initiates

Buy

Reason

HC Wainwright & Co.

Mitchell Kapoor

Strong Buy

Reiterates

$45

2024-12-20

Reason

HC Wainwright & Co.

Mitchell Kapoor

Price Target

$45

2024-12-20

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Mitchell Kapoor

Strong Buy

Reiterates

$45

2024-11-25

Reason

HC Wainwright & Co.

Mitchell Kapoor

Price Target

$45

2024-11-25

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Mitchell Kapoor

Strong Buy

Reiterates

$45

2024-10-31

Reason

HC Wainwright & Co.

Mitchell Kapoor

Price Target

$45

2024-10-31

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Oruka Therapeutics Inc (ORKA.O) is -6.71, compared to its 5-year average forward P/E of -5.08. For a more detailed relative valuation and DCF analysis to assess Oruka Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.08

Current PE

-6.71

Overvalued PE

-4.03

Undervalued PE

-6.12

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00